Johan Palm

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 150 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

Maria Karlgren, Gustav Ahlin, Christel A. S. Bergström et al. · Pharmaceutical Research · 2011 · 119 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Harma Ellens, Shibing Deng, JoAnn Coleman et al. · Drug Metabolism and Disposition · 2013 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Development of a Highly Sensitive Method Using Liquid Chromatography-Multiple Reaction Monitoring to Quantify Membrane P-Glycoprotein in Biological Matrices and Relationship to Transport Function

Tasso Miliotis, Liaqat Ali, Johan Palm et al. · Drug Metabolism and Disposition · 2011 · 38 citations

Medicine, Biochemistry, Pharmacology +17

A P-gp vesicular transport inhibition assay – Optimization and validation for drug–drug interaction testing

Krisztina Herédi‐Szabó, Johan Palm, Tommy B. Andersson et al. · European Journal of Pharmaceutical Sciences · 2013 · 36 citations

Medicine, Pharmacokinetics, Pharmacology +15